Welcome to our dedicated news page for Illumina (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Illumina's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Illumina's position in the market.
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announces multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop high-performing molecular tests for decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx NGS instrument, part of Veracyte’s expanded IVD approach. The first tests to be developed are Prosigna Breast Cancer Assay and Percepta Nasal Swab test, aimed at improving diagnostic and treatment decisions for breast cancer and lung nodules. Illumina's NextSeq 550Dx instrument offers validated mid-throughput platform with regulatory approvals in over 60 countries, broadening market access and enabling faster turnaround times for patients and physicians.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
-
Rhea-AI Summary
Environmental DNA collection kits developed by the molecular surveillance team at New Zealand's Cawthron Institute were used by a sailor during a solo race, showcasing their potential to provide near-real-time biological data about marine communities and support environmental sustainability efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
-
Rhea-AI Summary
Aegis Sciences Corporation, a US lab, has expanded its surveillance efforts to respond to emerging pathogens and improve public health. Originally focused on anti-doping testing and genetic testing for cancer clinical trials, Aegis rapidly scaled up its COVID diagnostic testing capacity during the pandemic. With the capability to conduct 130,000 PCR tests per day, Aegis helped the CDC monitor changes in SARS-CoV-2 by sequencing thousands of samples per week using the Illumina COVIDSeq Test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.25%
Tags
Rhea-AI Summary
Illumina Inc. has announced the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), a new generation of its distributed liquid biopsy assay for genomic profiling. The TSO 500 ctDNA v2 offers faster turnaround time, greater analytical sensitivity, and a more streamlined workflow. Key improvements include a sample-to-answer turnaround time of less than four days, higher sensitivity with lower cell-free DNA input requirements, and automation capabilities in 2024. The assay aims to enable noninvasive comprehensive genomic profiling of circulating tumor DNA to complement tissue-based testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
-
Rhea-AI Summary
The Mining Microbiome Analytics Platform is finding tiny solutions to some of our biggest environmental challenges. The mining industry is on the cusp of a staggering increase in demand for materials critical for low-carbon and renewable energy technology. Teck has built 'saturated rock fills' treated with special bacteria to reduce selenium levels in water. Microbes can also make mining itself more environmentally friendly. The Canadian government's Digital Supercluster initiative has formed the cross-industry Mining Microbiome Analytics Platform (M-MAP) to discover and implement these organisms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
-
Rhea-AI Summary
Illumina included on 2023 list of 100 Best Corporate Citizens
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
Rhea-AI Summary
Illumina launches microsite to educate healthcare professionals and promote whole-genome sequencing for genetic diagnosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
-
Rhea-AI Summary
HCA Healthcare and GRAIL collaborate to advance comprehensive cancer care through early detection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
-
Rhea-AI Summary
Illumina ordered by the European Commission to divest GRAIL
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
Rhea-AI Summary
Emma Johnson wins Illumina's Polygenic Risk Scores Research Grant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
Illumina Inc
Nasdaq:ILMN
ILMN Rankings
ILMN Stock Data
19.60B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
United States of America
SAN DIEGO
About ILMN
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.